SANSCO SERVICES - Annual Reports Library Services - www.sansco.net **Fourteenth Annual Report** 1999-2000 ANMOL

**Anmol Drugs & Pharmaceuticals Limited** 

## **Anmol Drugs & Pharmaceuticals Limited**

## DIRECTORS

Shri Ajay Kumar Jain

Wholetime Director

Shri Rajat Kumar Jain

Wholetime Director

Shri Sudarshan Kumar Jain

Director

Shri Vikram Rai

Director Director

Shri Pradeep Jain Shri L.V. Kannon

Director

## **GENERAL MANAGER (FINANCE)**

Şhri R.P. Singh

## **AUDITORS**

H. D. Sachdeva & Associates *Chartered Accountants* New Delhi

## SOLICITORS

Dhir & Dhir Associates New Delhi

## MAIN BANKERS

Bank Of India

## REGISTERED OFFICE

1496 (F.F) Bhagirath Place Chandni Chowk Delhi - 110 006

## WORKS

8/29, Kirti Nagar Industrial Area New Delhi

49, Mile Stone Delhi Rohtak Road Sampla, Dist. Rohtak Haryana

# SANSCO SERVICES - Annual Reports Library Services - www.sansco.net Pharmaceuticals Limited

#### NOTICE

Notice is hereby given that the 14th Annual General Meeting of the members of Anmot Drugs & Pharmaceuticals Limited will be held on Friday, the 29th September, 2000 at 10.00 A.M. at Community Centre, Neelwal Village, Delhi, to transact the following business:

## **ORDINARY BUSINESS**

- To receive, consider and adopt the audited Balance Sheet as on 31st March, 2000 and the Profit and Loss Account for the financial year ended on that date and the Reports of Directors and Auditors thereon.
- 2. To appoint a Director in place of Sh. Sudarshan Kumar Jain, Director, who retires by rotation and being eligible, offers himself for re-appointment.
- To appoint a Director in place of Sh. L. V. Kannon, Director, who retires by rotation and being eligible, offers himself for re-appointment.
- 4. To appoint Auditors to hold office from the conclusion of this Annual General Meeting until the conclusion of next Annual General Meeting and to fix their remuneration. M/s H. D. Sachdeva & Associates, Chartered Accountants, the retiring Auditors of the Company are eligible for re-appointment.

By Order of the Board For Anmol Drugs & Pharmaceuticals Ltd.

Registered Office 1496, (FF) Bhagirath Place Chandni Chowk Delhi-110 006

Rajat Jain Wholetime Director

Dated: 28th August, 2000

#### NOTES

- A member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote instead if himself and the proxy need not be a member of the company. Proxies, in order to be-effective, must be received by the Company not less than 48 hours before the meeting.
- ii) The Register of Members and Share Transfer Books of the Company shall remain closed from 14th September, 2000 to 29th September, 2000 (both days inclusive).
- iii) Members are requested to notify immediately any change in their address, quoting folio numbers to the Company.
- iv) Members are requested to bring their copy of Annual Accounts at the meeting, as extra copies may not be available.
- Members are requested to notify any correspondence relating to transfer of shares/ change of address may please be sent to the registered office of the Company.

By Order of the Board

For Anmol Drugs & Pharmaceuticals Ltd.

Registered Office 1496, (FF) Bhagirath Place Chandni Chowk Delhi-110 006

Rajat Jain Wholetime Director

Dated : 28th August, 2000

13.

#### **DIRECTORS' REPORT**

To the Members of Animal Druge & Pharmacouticals Ltd.

Your Directors have pleasure in submitting the 14th Annual Report and Audited Statement of Accounts of the Company for the year ended 31st March, 2000.

#### Financial Results

perult of the financial year and proposed appropriations as compared to the previous year are as under:

(Rs. in Lacs)

Sec. 1	For the Year Ended 31.03.2000	For the Year Ended 31.03.99
Profit/(Loss) before Tax & Depreciation	(75.96)	(132.09)
- Depreciation	2.75	3.26
Profit/(Loss) before Tax	(78.71)	(135.35)
Extra Ordinary Items (Waiver of Tax Liability)	· –	108.25
ा <del>हर</del> ः Tax	<u> </u>	-
Profit/(Loss) after Tax	(78.81)	(27.10)
	(5.54)	(4.67)
Profit available for Appropriation	<u> </u>	<u> </u>
Appropriations		
- General Reserve		
Proposed Dividend	<u> </u>	
Balance carried to Balance Sheet	(315.04)	(230.79)

## Operations

**During** the year under review, the operations were adversely affected due to lower level of capacity utilisation, sluggish and competitive market and overall economic recession.

The turnover of the Company has fallen by 67% which is Rs.58.30 Lacs as compared to previous year of Rs.179.16 Lacs. Inspite of best efforts the Company is not able to recover its debts. Keeping that in view, the Company has written off Rs.23.15 Lacs as Bad Debts as the same are not recoverable. The Board has also decided the provision for doubtful debts of Rs.20.35 Lacs. The Company is regularly incurring continued tosses.

## Particulars of Energy Conservation etc.

In accordance with requirements of Section 217 (i) (e) of the Companies (Disclosure of the particulars in the Report of the Board of Directors) Rules, 1988, statement showing salient features in respect of Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Outgo are annexed and form part of this report.

## Particulars of Employees

There are no employees within the meaning of Section 217 (2A) of the Companies Act, 1956 read with the Companies (Particulars of Employees) Rules, 1975 as amended.

## SANSCO SERVICES - Annual Reports Library Services - www.sansco.net Pharmaceulicals Limited

#### Industrial Relations

Relations with the employees continued to remain cordial throughout the year. Your Directors wish to place on record their high appreciation for dedicated and sincere services rendered by the Executives, Staff and Workmen at all levels.

#### Auditors

The term of office of M/s H. D. Sachdeva & Associates, Chartered Accountants, Auditors of the Company expires at the conclusion of the forthcoming Annual General Meeting. They have expressed their willingness to be re-appointed and are eligible for re-appointment

#### Auditors' Observation

The observation of the Auditors in the audit report have been explained in the Notes to Accounts, which are self explanatory.

#### Dividend

In view of losses during the year, the Directors regret their inability to recommend payment of dividend.

#### Directors

Sh. Sudarshan Kr. Jain and Sh. L. V. Kannon, Directors, retire by rotation and being eligible offer themselves for reappointment.

#### Acknowledgements

Your Directors are pleased to place on record their high appreciation for the valuable co-operation and support received from Banks and dedication and commitment of the staff at all levels without which the all round growth and progress of the Company could not have been possible.

3

For and on behalf of the Board

Ajay Jain Rajat Jain (Wholetime Directors)

Place: New Delhi

Date: 28th August, 2000

Report Junction.com

SANSCO SERVICES - Annual Reports Library Services - www.sansco.net Annual Drugs &

## **Pharmaceuticals Limited**

ANNEXURE TO DIRECTORS' REPORT					
CONS	ERVATION OF ENE	RGY		<del></del>	
(A) P	ower & Fuel Consu	mption	* Current Year	Previous Year	
s Mes ( 🚓 )	Electricity	1			
Maria	(i) Purchased Units		<b>-</b> •	_ •	
Marie "	Total Amount (Rs.	.)	127452.00	148309.00	
(Øse).	Rate/Unit (Rs.)		- *	• ·	
Electric	city Department is se	nding the bill	on		
	e basis and not on th	•			
	g, so figure of units po				
rate/ur	it for current year is r	ot available.		•	
*	(ii) Own Generation T	hrough Diesel	Generator		
e ∰114.	Through Steam Tu	rbine/Generato		<u> </u>	
	Unit		_	_	
	Unit per liter of Fu	el Oil/Gas	.—		
ied ( )	Cost/Unit		_	· · · · · · · · · · · · · · · · · · ·	
	Coal		•		
	Quantity (Tonnes)		<b>-</b> ,		
tancu.	Total Cost		<b>–</b> "	****	
tio:	Average Gas		•	· · · · · · · · · · · · · · · · · · ·	
gorri G.	Furnaçe Oil				
	Quantity (Kilo Liters)		_		
- m.C.	Total Amount	r (Ba)	<del>-</del>	_	
	Average Rate per lite		_	. –	
let in	Other/Internal Gener	ation		* 1	
	Quantity Total Cost			<del>_</del>	
	Rate/Unit		<del>-</del> "	Mariana (m. 1945) Mariana (m. 1947)	
#1 5			<b>—</b> ·		
e .	onsumption per Uni Init of Products (1000		doe)		
1.7	lectricity per	No Stand			
	nit of production	is fixed t		com	
\$4.	01.0/1	it depend	ds upon		
N.		product i	mix		
	ted earlier figure of ur		<del>-</del>		
	the year is not availa				
N .	med per unit of produc	Juon Cannot De	determined.		
K	omace Oil		<del></del>	_	
童 67。	ical Others			_	
14					
	dditional investment	, ,	•	Nil	
f , .	any, being impleme f consumption of en		CHOTI	•	
		~· <b>3</b> /·			

## SANSCO SERVICES - Annual Reports Library Services - www.sansco.net

## Pharmaceuticals Limited

#### 2. TECHNOLOGY ABSORPTION

## Efforts made in Technology Absorption:

#### A. Specific areas in which R & D carried out by the Company

The Company is planning to have a separate R & D Department for the development of new medicines and inprovement of existing medicines. The Company is having highly qualified and computer technical staff who carries on R & D activities and make improvement in existing products and develop new products.

## B. Benefit derived as a result of the above R & D

Various improvements have been made in the medicines produced by the Company as a result of R & D activities undertaken by the Company.

## C. Future Plans of Action

All existing projects in Pharmaceuticals development are to be continued with the induction of various new sophisticated instruments.

#### D. Expenditure on R & D

Since the Company is not having a separate R & D Department figure of expenditure on R & D is not separately available.

## E. Technology Absorption, Adaptation and Innovation

- a. Efforts Made
  - Efforts are being made innovating indifferent fields including adoption of latest technology.
- Benefits derived as a result of the above efforts e.g. product improvement, cost reduction, product developments etc.
- Imported technology (Imported during the last 5 years reckaned from the beginning of the Financial year):

The Company has not imported any technology.

#### 3. FOREIGN EXCHANGE EARNING AND OUTGO

	1999-2000	1998-99
	(Rs. in Lacs)	(Rs. in Lacs)
Total Foreign Exchange Earned	Nil	Nil
Total Foreign Exchange Used	Nil	Nil

For and on behalf of the Board

Ajay Jain Rajat Jain (Wholetime Directors)

Place: New Delhi

Date : 28th August, 2000

## Pharmaceuticals Limited

To the Members of

10.100

學

\*\*

Anmol Druge & Pharmaceuticals Ltd.

We have audited the attached Balance Sheet of Anmol Drugs & Pharmaceuticals Ltd. as at 31st March, 2000 and also the Profit & Loss Account for the year ended on that date annexed thereto and report that:

**AUDITORS' REPORT** 

- 1. As required by the manufacturing and other Companies (Auditor's Report) Order, 1988, issued by the Company Law Board in terms of Section 227 (4A) of the Companies Act, 1956, we give in the Annexure a statement on the matters specified in paragraph 4 and 5 of the said order to the extent applicable to Company.
- 2. Further to our comments in the Annexure referred to in paragraph (1) above, we report that:
  - (a) Subject to Note No. 6 regarding non-receipt of confirmations in respect of receivables and payables. Note No. 13 regarding non provision of valuation report relating the Capital Work in Progress, Note No. 16 regarding valuation of stock of finished goods on cost basis, we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet and Profit and Loss Account dealt with by this report are in agreement with the books of account.
- (d) In our opinion, the Profit & Loss Accounts and Balance Sheet comply with the Accounting Standard referred to Section 211 (3C) of the Companies Act, 1956 except Note No. 16 varuation of finished goods has been made on the basis of adjusted selling price method.
  - Dividend for financial year 1993-94 amounting to Rs.52,892.88 interest thereon Rs.41,256/- outstanding at the beginning of the year and declared by the Company in its 8th Annual General Meeting held og 30.09.94 & for the financial year 1994-95 amounting to Rs.10,16,331.25 and interest thereon of Rs.6,70,780.00 declared by the Company in its 9th Annual General Meeting held on 29.12.95 has not been paid by the Company within forty two days from the date of declaration and amount of dividend remaining unpaid or unclaimed has not been transferred to a separate Unpaid Dividend Account in any Scheduled Bank till the date of finalisation of accounts. In our opinion, this is in contravention of the requirements of Section 205-A of the Companies Act, 1956.

Subject to the matters referred to in paragraphs (a), (d) (i) and Note No. 3A(i) regarding from a provision of amount under dispute with customers of Rs.2,11,017.00, Note No. 3A(ii) regarding interest on Sales Tax liability of Rs.2.52 Lacs, Note No. 6 regarding from confirmation of recoverables & payables, Note No. 9 regarding provision for bad & doubtful debts amounting to Rs.111.61 Lacs against non operating & doubtful Sundry Debtors of Rs.202.91 Lacs on Note No. 12 regarding statement of amount of Capital Work in Progress as per the Books of Account, in the absence of any valuation report, Note No. 13 regarding valuation and valuation as certified by the Management, Note No. 15 relating to preparation of accounts on